Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Feb;36(2):1013-1022.
doi: 10.1002/ptr.7374. Epub 2022 Jan 12.

Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial

Elaheh Honarkar Shafie  1 , Fateme Taheri  1 , Neda Alijani  2 , Ahmad Reza Okhovvat  3 , Razieh Goudarzi  1 , Nasrin Borumandnia  4 , Leila Aghaghazvini  5 , Seyed Mahdi Rezayat  6 , Saeidreza Jamalimoghadamsiahkali  7 , Mohammad Javad Hosseinzadeh-Attar  1
Affiliations
Randomized Controlled Trial

Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial

Elaheh Honarkar Shafie et al. Phytother Res. 2022 Feb.

Abstract

It has been more than a year since the outbreak of COVID-19, and it is still the most critical issue of the healthcare system. Discovering effective strategies to treat infected patients is necessary to decrease the mortality rate. This study aimed to determine the effects of nanocurcumin on the severity of symptoms and length of hospital stay (LOS) in COVID-19 patients. Forty-eight COVID-19 patients were randomly assigned into nanocurcumin (n = 24) and placebo (n = 24) groups receiving 160 mg/day nanocurcumin or placebo capsules for 6 days. Mean differences of O2 saturation were significantly higher in patients who received nanocurcumin supplements (p = 0.02). Also, nanocurcumin treatment significantly reduced the scores of domains 3 and 4 and the total score of Wisconsin Upper Respiratory System Survey (WURSS-24), indicating milder symptoms in the treatment group (p = 0.01, 0.03, and 0.01 respectively). Besides, the LOS in curcumin groups was lower than in the placebo group, although the difference was not statistically significant (6.31 ± 5.26 vs. 8.87 ± 8.12 days; p = 0.416). CBC/differentiate, hs-CRP level and the pulmonary involvement in CT scan were not different between the two groups. As nanocurcumin can be effective in increasing O2 saturation and reducing the severity of symptoms in COVID-19 patients, it could probably be used as a complementary agent to accelerate the recovery of patients.

Keywords: COVID-19; CT scan; hs-CRP; nanocurcumin.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Adibian, M., Hodaei, H., Nikpayam, O., Sohrab, G., Hekmatdoost, A., & Hedayati, M. (2019). The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Phytotherapy Research, 33(5), 1374-1383.
    1. Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The International Journal of Biochemistry & Cell Biology, 41(1), 40-59.
    1. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807-818.
    1. Bahrs, C., Kimmig, A., Weis, S., Ankert, J., Hagel, S., Maschmann, J., Stallmach, A., Steiner, A., Bauer, M., Behringer, W., Baier, M., Kesselmeier, M., Richert, C., Zepf, F., Walter, M., Scherag, A., Kiehntopf, M., Löffler, B., & Pletz, M. W. (2021). Prospective surveillance study in a 1,400-bed university hospital: COVID-19 exposure at home was the main risk factor for SARS-CoV-2 point seroprevalence among hospital staff. Transboundary and Emerging Diseases, https://doi.org/10.1111/tbed.14041
    1. Barrett, B., Brown, R., Mundt, M., Safdar, N., Dye, L., Maberry, R., & Alt, J. (2005). The Wisconsin upper respiratory symptom survey is responsive, reliable, and valid. Journal of Clinical Epidemiology, 58(6), 609-617.

Publication types

-